Showing results (1-10 of 190) with videos related to
Sort By:
Pageof 19
Current Oncology Reports|May 24, 2024
Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma TherapyAndrew D Knight, Jason J LukeThe Oncologist|May 9, 2019
Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic MelanomaJason J LukeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2022
Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint BlockadeValsamo Anagnostou, Jason J LukeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 ImmunotherapyLilit Karapetyan, Jason J LukeCurrent Oncology Reports|September 11, 2016
Optimal Use of BRAF Targeting Therapy in the Immunotherapy EraKevin Wood, Jason J LukeThe Oncologist|May 28, 2013
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaJason J Luke, F Stephen HodiClinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2011
Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanomaJason J Luke, F Stephen HodiClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Autoantibodies as Predictors for Clinical Outcome and Toxicity for ImmunotherapyJessica C Hassel, Jason J LukeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2023
Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint BlockadeRichard C Wu, Jason J LukePageof 19